Crystalline form of a quinolinone-carboxamide compound

Patent metadata

Field	Value
Publication number	US-9402840-B2
Application number	US-201514816237-A
Country	US
Kind code	B2
Filing date	Aug 3, 2015
Priority date	Apr 6, 2005
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT 4 receptor activity, and processes useful for preparing such crystalline salt forms.

First claim

What is claimed is:

1. A method of treating a disorder of reduced motility of the gastrointestinal tract in a mammal, wherein the disorder of reduced motility is chronic constipation, constipation-predominant irritable bowel syndrome, gastroparesis, drug-induced delayed transit, or functional dyspepsia, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutical carrier and a crystalline hydrate of the hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide which is characterized by a thermal gravimetric analysis trace substantially in accordance with the bottom trace in FIG. 5 and by a powder x-ray diffraction pattern having diffraction peaks at 2θ values of 10.52±0.2, 13.85±0.2, 15.80±0.2, 17.26±0.2, and 21.06±0.2.

2. The method of claim 1 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by diffraction peaks at 2θ values of 5.30±0.2, 7.43±0.2, 8.72±0.2, 10.52±0.2, 13.85±0.2, 14.11±0.2, 15.80±0.2, 15.99±0.2, 17.26±0.2, 19.53±0.2, 20.08±0.2, 21.06±0.2, 21.48±0.2, 21.92±0.2, 22.85±0.2, 23.91±0.2, 25.28±0.2, 26.06±0.2, 27.34±0.2, 27.51±0.2, and 29.67±0.2.

3. The method of claim 1 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 4 .

4. The method of claim 1 wherein the crystalline hydrate is further characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 5 .

5. A method of treating gastroparesis in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutical carrier and a crystalline hydrate of the hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide which is characterized by a thermal gravimetric analysis trace substantially in accordance with the bottom trace in FIG. 5 and by a powder x-ray diffraction pattern having diffraction peaks at 2θ values of 10.52±0.2, 13.85±0.2, 15.80±0.2, 17.26±0.2, and 21.06±0.2.

6. The method of claim 5 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by diffraction peaks at 2θ values of 5.30±0.2, 7.43±0.2, 8.72±0.2, 10.52±0.2, 13.85±0.2, 14.11±0.2, 15.80±0.2, 15.99±0.2, 17.26±0.2, 19.53±0.2, 20.08±0.2, 21.06±0.2, 21.48±0.2, 21.92±0.2, 22.85±0.2, 23.91±0.2, 25.28±0.2, 26.06±0.2, 27.34±0.2, 27.51±0.2, and 29.67±0.2.

7. The method of claim 5 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 4 .

8. The method of claim 5 wherein the crystalline hydrate is further characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 5 .

9. A method of treating chronic constipation or constipation-predominant irritable bowel syndrome in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutical carrier and a crystalline hydrate of the hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide which is characterized by a thermal gravimetric analysis trace substantially in accordance with the bottom trace in FIG. 5 and by a powder x-ray diffraction pattern having diffraction peaks at 2θ values of 10.52±0.2, 13.85±0.2, 15.80±0.2, 17.26±0.2, and 21.06±0.2.

10. The method of claim 9 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by diffraction peaks at 2θ values of 5.30±0.2, 7.43±0.2, 8.72±0.2, 10.52±0.2, 13.85±0.2, 14.11±0.2, 15.80±0.2, 15.99±0.2, 17.26±0.2, 19.53±0.2, 20.08±0.2, 21.06±0.2, 21.48±0.2, 21.92±0.2, 22.85±0.2, 23.91±0.2, 25.28±0.2, 26.06±0.2, 27.34±0.2, 27.51±0.2, and 29.67±0.2.

11. The method of claim 9 wherein the powder x-ray diffraction pattern of the crystalline hydrate is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 4 .

12. The method of claim 9 wherein the crystalline hydrate is further characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 5 .

Assignees

• Fatheree Paul R
• Turner S Derek
• Goldblum Adam A
• Chao Robert S
• Genov Daniel
• Theravance Biopharma R&D Ip Llc

Inventors

• Fatheree Paul R
• Turner S Derek
• Goldblum Adam A
• Chao Robert S
• Genov Daniel

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P1/10

  Laxatives · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title